Here at Vivisum Partners, we’re committed to providing you with the most actionable market research available. That’s why we’ve created the new Oral Type 2 Diabetes Market Landscape library that provides up-to-date insights and trends about the oral treatments for type 2 diabetes, which is growing quickly as new therapies enter the market.
The new research library comprising 15 in-depth reports that provide real-world insights collected from more than 150 endocrinologists and primary care providers. The library includes 7 strategy guides covering the following brand considerations for oral type 2 diabetes medications:
- Target patient analysis
- HCP prescription journey
- Competitive landscape
- Unmet needs in the marketplace
- Brands’ rational benefits
- Brand personalities and emotional benefits
- Clinical pipeline analysis
In addition to the strategy guides, the research library also includes 8 brand navigators that provide detailed healthcare providers (HCPs) perspectives and insights on the following oral type 2 diabetes drugs:
- Farxiga
- Januvia
- Jardiance
- Invokana
- Onglyza
- Rybelsus
- Steglatro
- Tradjenta
Oral type 2 diabetes drugs include GLP-1 agonists, SGLT-2 inhibitors and DPP-4 inhibitors. The market for oral type 2 diabetes drugs is becoming increasingly competitive due to the approval of new drugs, many of which are seeing strong early uptake.
In the U.S., there has been significant approval activity in the past 5 years among SGLT-2 inhibitors, such as Jardiance and Farxiga, and DPP-4 inhibitors, including Januvia and Tradjenta. GLP-1 agonists are showing strong growth due to superior A1C efficacy, improvements in weight loss and patient satisfaction with weekly or monthly dosing.
Increased competition among oral type 2 diabetes treatments
Oral Type 2 Diabetes Competitive Landscape, recently published by Vivisum Partners, found that the market for oral type 2 diabetes drugs is becoming increasingly competitive due to the strength of the development pipeline, including oral insulin (ORMD-0801), which 76% of surveyed HCPs believe will provide better efficacy than existing treatments. The launch of these treatments is sure to put pressure on existing oral type 2 diabetes treatments.
Within the oral type 2 diabetes landscape, GLP-1 agonists, such as Rybelsus and Oramed’s ORMD-0801 (oral insulin), are showing strong growth due to superior A1C efficacy, improvements in weight loss and patient satisfaction with weekly or monthly dosing. According to Vivisum’s research, HCPs believe that oral insulin will surpass the current arsenal of type 2 diabetes oral medications in efficacy, tolerability and support.
Key competitor insights about oral type 2 diabetes medications
Jardiance is a popular treatment and has the highest patient share of any branded drug. It is also expected to see one of the largest increases in prescriptions over the next 12 months out of the type 2 diabetes oral category.
Endocrinologists and primary care providers, however, see Rybelsus as on the rise. The majority of HCPs expect Rybelsus to increase in prescriptions over the next year. While the brand does not rank highly in current patient share, it is the branded drug with the largest expected increase in prescriptions.
Jardiance has its competitors, though. HCPs see Jardiance as a strong competitor to both Farxiga and Invokana. This indicates that the SGLT2s are competing for market share against one another.
What’s shaping the oral type 2 diabetes market?
The market for oral type 2 diabetes drugs is growing quickly as new therapies enter the market. GLP-1 agonists are showing strong growth due to superior A1C efficacy and improvements in weight loss and patient satisfaction with weekly or monthly dosing. SGLT-2 inhibitors are expected to continue growing despite increased competition with each other.
The Oral Type 2 Diabetes Market Landscape research library provides detailed analysis and market insights about available oral type 2 diabetes treatments, as well as pipeline therapies. The strategy guides and brand navigators in this research provide life sciences executives with primary research on endocrinologists’ and primary care providers’ perceptions of branded and pipeline type 2 diabetes treatments. The market insights included in the research are supported by HCPs’ direct quotes and expectations for how the oral type 2 diabetes landscape is currently shaped and how it will change due to emerging trends.
